Clifford Fong. The effect of desolvation on the binding of inhibitors to HIV-1 protease and cyclindependent kinases: Causes of resistance. Bioorganic and Medicinal Chemistry Letters, Elsevier, 2016, 26, pp
• To examine what impact the desolvation of ligand and protein has on ligand-protein binding and resistance to binding with HIV-1 proteases and cyclin-dependent kinases • To examine the applicability of a novel four parameter QSAR method to ligand-enzyme binding of HIV-1 proteases and cyclin-dependent tyrosine kinases
This study will use a model (equation 1 or 1a) which has been successfully applied to various transport and drug-protein binding processes. A common model for both processes based on 4 molecular physico-chemical properties of the prospective drugs has been previously applied to passive and facilitated diffusion, and active organic anion transporter drug membrane transport, some competitive statin-CYP enzyme binding processes and some tyrosine kinase inhibitors. 1, 2, 3 The model comprises four main properties: (a) desolvation energy in water (b) lipophilicity or hydrophobicity based on the solvation energy in a hydrophobic solvent such as n-octane or n-octanol; lipophilicity being a measure of how well a drug can interact with lipophilic cell membrane bilayers, and hydrophobicity being a measure of non-polar interaction between a drug and the hydrophobic sectors of a protein (c) dipole moment in water, as a measure of the polar attraction between the drug and its receptor target or cell membrane (d) the molecular volume of the drug in water as a measure of how well the prospective drug fits into the cavity of the target receptor protein or active protein transporter, or how well a drug can diffuse through a cell membrane. The basic model is shown in equation 1. It has been shown that equation 1 can be successfully applied to the competitive binding of a number of tyrosine kinase inhibitors and multi-kinase inhibitors to a range of kinase enzymes. Equation 1 also applies to the active competitive transport of these tyrosine kinase inhibitors by the hOCT3, OATP1A2 and OCT1 transporters. ΔG desolvation = ΔG electrostatic + ΔG CDS where CDS is the cavity dispersion solvent structure. The CDS involves non-bulk solvent electrostatic contributions to the free energy of hydration. The SMD solvation model is based on ΔG S o = ΔG ENP + G CDS where ENP is the electronic nuclear polarization: the change in the solute free energy due to electrostatic interactions between the solute and the bulk solvent and distortion of the solute's electronic structure in solution. The solvent is modelled as a dielectric continuum. The CDS represents first solvation shell effects. It involves atomic surface tension (geometry dependent proportionality constants). The CDS has been parameterized using extensive experimental data sets for optimization, and has the advantage of including a realistic experimentally based hydrogen bonding model. The CDS covers shorter-range polarization effects and shorter-range non-electrostatic effects such as cavitation, dispersion, and solvent structural effects (which includes both hydrogen bonding) and exchange repulsion effects. 4 ΔG desol,CDS can be substituted for ΔG desolvation where this nonpolar term may be more representative of the interaction processes being studied, as for example in a ligand-protein binding study within the protein binding pocket where the dielectric constant for that environment is ca. ε=7-10 compared to ε=78.3 for the bulk water environment where the use of ΔG desolvation is more appropriate. 3 It has been shown that continuum based hydrophobic non-polar hydration solvation models can fairly accurately model particular protein-protein and ligand-protein complexes, although different protein systems may have unique attractive (van der Waals) properties not precisely transferable to other systems. 5 The hydration hydrophobic effect is primarily due to a decrease in the number of ways that favourable hydrogen bonding can be achieved by solvent water molecules when they are near to a non-hydrogen bonding solute, thereby decreasing the solvent's entropy. The hydrophobic non-polar hydration free energy ΔG non-polar can be considered to comprise of the repulsive ΔG cavity and attractive ΔG vdw terms. The ΔG cavity term includes the repulsive electrostatic effect of forming a cavity in the solvent whereby the solute interacts with the water solvent, while the ΔG vdw term includes shorter-range polarization effects and shorter-range non-electrostatic effects such as cavitation, dispersion, and solvent structural effects (which includes both hydrogen bonding) and exchange repulsion effects.
When a solvated ligand enters a protein binding cavity and begins to bind with the protein, the desolvation processes involving the protein and ligand may involve extensive rearrangement of water molecules, and possibly some expulsion of water molecules from the cavity. A significant change in solvation entropy should then occur on the side on the ligand and the protein receptor.
In this study it is postulated that the ΔG desolv,CDS values may be a close approximation of how a solvated inhibitor reacts as it approaches and starts to enter the binding pocket (dielectric constant ε=20-30) and leaves the bulk water environment (ε =78.3) and binding starts to occur. This scenario has been modelled using more intensive molecular mechanics computations. [6] [7] [8] It has also been shown 2 that equation 1 can be modified to model redox processes (eg metabolic oxidation of statins by CYP enzymes) particularly when the molecular volume changes are small. The electron affinity EA or ionization potential IE in water are measures of the ease that drugs can be reduced or oxidised by appropriate species such as enzymes.
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HIV-1 Protease Inhibitors
Human immunodeficiency virus (HIV) is a lentivirus and HIV-1 causes the majority of the acquired immune deficiency syndrome (AIDS) epidemic. The development of selective approved inhibitors (Figure 1 ) for the HIV-1 protease within a short period is considered a notable success of molecularly designed drug development. 9 Despite the success of the approved inhibitors, mutation induced resistance is a major problem facing the treatment of AIDS. The causes of resistance are not well understood. This study will focus on one study where it was suggested that desolvation of the inhibitors was an important factor in protease resistance.
Figure 1. Structures of approved HIV-1 Protease inhibitors

Cyclin-dependent Kinase Inhibitors
Cyclin-dependent kinases (CDKs) are among the most important of the many proteins involved in cell cycle control. CDKs are a family of multifunctional enzymes that can modify various protein substrates involved in cell cycle progression. Specifically, CDKs phosphorylate their substrates by transferring phosphate groups from ATP to specific stretches of amino acids in the substrates. Cyclins are a family of proteins that have no enzymatic activity of their own but activate CDKs by binding to them. CDKs must also be in a particular phosphorylation state. CDKs are potential targets for anti-cancer therapy. If it is possible to selectively interrupt the cell cycle regulation in cancer cells by interfering with CDK action, the cell will die. (Figure 2 ) Various CDK inhibitors have been approved or are being trialled for their anti-cancer potential.
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Figure 2. Relationships amongst cyclin-dependent kinases CDK and cell cycle phases and effect of inhibitors (4-Butoxy-1H-pyrazolo [3,4-b] pyridin-5-yl)(phenyl)methanone (SQ-67563) has been shown to be a potent, selective inhibitor of CDK1 (IC 50 =0.15 μM) and CDK2 (IC 50 =0.11 μM) in vitro which binds at the ATP site. 13, 14 In cells SQ-67563 acts as a cytotoxic agent with the ability to block cell cycle progression and/or induce apoptosis. The X-ray structure shows SQ-67563 bound to CDK2 resides coincident with the ATP purine binding pocket and forms important H-bonding interactions with Leu83 on the protein backbone via the two N atoms of the pyrazolopyridine ring. The carbonyl group does not appear to be involved in any interaction with the CDK2 protein. Phenyl groups attached to the carbonyl group engage in π stacking with the Phe80 of the protein. Although the 4 position tolerated a wide number of large lipophilic substituents it was found that the introduction of smaller polar substituents at this location did not result in any activity against the CDK inhibitors. (Figure 3 ) The 4-alkoxy substituents extends into the space occupied by the ribose of ATP and does not appear to form any specific contacts with the protein. It was thought that the energetic penalty incurred during desolvation of the polar groups compromises the overall observed binding affinity.
13,14
Applying Equation 1 to HIV-1 Protease Inhibitors
The inhibitory effect of nine approved HIV inhibitors on a WT HIV-1 protease and four multi-drug resistant (MDR) HIV-1 proteases has been previously examined. The IC 50 values for darunavir, atazanavir, lopinavir, tipranavir, nelfinavir, amprenavir, saquinavir, indinavir, ritonavir with the NL-43 WT HIV-1 protease, and the four clinical MDR HIV-1 protease variants, MDR 769, MDR 807, MDR 1385, and MDR 3761have been determined. The four MDR protease variants were resistant to all of the FDA-approved HIV-1 protease inhibitors at various levels, compared to the WT HIV-1 protease. 10 From a molecular mechanics study of the ligand binding to the protease MDR769, it was concluded that desolvation energy plays an important role in the ligand entry and proteaseligand complex formation. The MDR proteases required a higher energy to desolvate the substrate and the protease active site. The higher desolvation barrier for MDR proteases increases the difficulty of protease-ligand complex formation. From the crystal structure and direct measurement using pulsed double electron-electron resonance (DEER), it was found that there was a larger distance between the flaps of MDR 769 compared to the wild-type protease structure. The wide-open conformation of the MDR protease in solution exposed more active site regions to solvent which may further elevate the desolvation barrier. It was found that the desolvation energy and the non-polar component (analogous to CDS) solvation energy of the HIV-1 protease-p2/NC complex for the NL-43 WT HIV-1 protease (178 and 7.6 kcal/mol), were lower than the MDR HIV-1 protease variants, MDR 769 (188 and 7.7 kcal/mol), MDR 807 (210 and 7.9 kcal/mol), MDR 1385 (228 and 7.6 kcal/mol), and MDR 3761 (256 and 7.7 kcal/mol), suggesting that resistance had some dependency on the desolvation energy of the proteases. 10 The high resolution X-ray and neutron structure of a HIV-1 protease -inhibitor complex has revealed the presence of water molecules as an integral part of the protease-inhibitor complex, particularly involved in 9 bridging (mediated) hydrogen bonds out of the 16 hydrogen bonds between the KNI-272 inhibitor and the protease HIV-1. This study and other related studies indicate that a number of water molecules are present in the inhibitor binding complexes formed with the HIV-1 proteases. HIV protease inhibitors usually contain a central core motif consisting of a hydroxyethylene scaffold. A critical feature is a hydroxyl group on the core motif which forms a hydrogen bond with the carboxylic acid on the Asp-25 and Asp-25´ residues in the binding site. Hydrogen bonds are formed between a water molecule, which is linked to Ile50 and Ile50', and carbonyl groups of the inhibitors are connected with the flap regions of the protease. Specific pockets in the binding site of the HIV protease, S1,S1',S2 and S2', recognize hydrophobic amino acids on natural substrates. 17 The potency of inhibitors bearing hydrophobic groups complementing these areas is therefore increased. 15 Mutations that are primarily in the active site of the HIV protease enzyme alter the conformational shape facilitate resistance to protease inhibitors. The cleavage sites have highly diverse sequences, so the protease recognizes its substrates by the conserved 3D shape (substrate envelope) the substrates share when bound at the active site. 16 The x-ray results 16, 17 and the protease solvation studies 10 suggest that there must be some preorganization of the water within the protease binding pocket as well as changes to the solvation shells surrounding the incoming inhibitors as they leave the bulk cellular water environment and approach and then enter the protease binding pocket. When the protease binds to its substrate and buries nearly 1000 Å 2 of surface area, the symmetry of the protease is broken, yet most internal hydrogen bonds and waters are conserved. However, no substrate side chain hydrogen bond is conserved. Also the substrate-protease complexes show large numbers of water molecues, and several water molecules which act as bridging entities between the inhibitor and protease. 16, 17 The specificity of HIV-1 protease appears to be determined by an asymmetric shape rather than a particular amino acid sequence.
Consideration of how the hydration shell around the inhibitor changes as the inhibitor leaves the bulk water environment, enters the protease binding pocket, and then binds to the protease is critical to understanding the role of solvation during the binding process. The dielectric constant ε, for the bulk water environment is ca. 78, and then changes as the inhibitor approaches the entry of the protease to ε of ca. 20-30, then to a ε of ca. 6-10 within the protease environment. 18, 19 It is also clear that hydrophobic interactions between the S1,S1',S2
and S2' protease sites and the hydrophobic regions of inhibitors is also an important factor. In the analysis below, ΔG solvation is considered to represent the inhibitor in the bulk water environment, the non-polar contribution to solvation, ΔG desol,CDS is considered to represent the solvation shell around the inhibitor as it binds to the enzyme, ΔG lipophilicity (the free energy of solvation in n-octane) represents the hydrophobic interaction between inhibitor and the enzyme, the dipole moment in water is taken to represent the polar interaction between the inhibitor and solvent and enzyme, and the molecular volume in water is taken to represent the molecular size of the solvated inhibitor.
The desolvation or dehydration, lipophilicity, dipole moment and molecular volumes of the various inhibitors are shown in the Table, and these values were used in deriving the following equations. It can be seen that eq 1, 1a and 1b are very similar. Eq 1 and 1a are IC 50 correlations from Wang 10 where the inhibitors were the neutral species, and the ΔG binding isothermal calorimetry values (kcal/mol) are from Freire 10a , where nelfinavir, saquinavir, indinavir, ritonavir were zwitterionic species which gave the best correlation. Clearly the HIV-1 proteases were different in each study, and experimental conditions were also different. The similarity of the three equations indicate that the general form of the four parameter equation eq 1 is substantially robust. It is apparent that the MDR proteases show very different behaviours than the WT protease, and MDR-769 and 807 are also quite different from MDR-1385 and 3761. The MDR proteases interact with the inhibitors with greater sensitivities to all four dependent variables than the wild type protease. This is consistent with Wang's observation that these latter two proteases have the higher solvation energies compared to MDR-769 and 807 (and the WT). The non-polar desolvation energies (CDS) for the proteases are 7.6 to 7.9 kcal/mol, which compares to a ligand range of 7.6 kcal/mol (ritonavir) to 17.7 kcal/mol (atazanavir). These data suggest that water solvent desolvation or solvent rearrangement energies are greater for the ligand than the receptor protein during binding, a key pointer regarding future drug development in these systems. It is noted that eqs 2-5 used the zwitterionic form for nelfinavir, saquinavir, indinavir, ritonavir since these species were large outliers from the eqs when included as neutral species, but gave consistently high correlations for all four MDR equations. Eqs 1 and 1a used the neutral form of the inhibitor species.
A common distinguishing feature is that all of the MDR proteases have much higher dependences on the dipole moment than the WT protease. Also molecular size does not seem to be a critical factor. The MDR-769 and 807 show a different class of interaction with the anti-viral drugs than MDR-1385 and 3761, particularly regarding their sensitivity to water desolvation, and lipophilicity. It would appear that the interactions with MDR-1385 and 3761 are driven by a more balanced non-polar, hydrophobic (or lipophilic) plus a hydrophilic interaction with the anti-virals than MDR-769 and 807 (and the WT protease even more so) which is more driven by hydrophilic interactions.
In summary, the resistance shown by MDR proteases to the anti-viral drugs is multi-faceted involving varying changes in desolvation, lipophilicity and dipole moment interaction compared to the non-resistant WT protease.
Applying Equation 1 to Cyclin-dependent Kinase Inhibitors
A study has been made of the inhibitory activity against CDK2/cycE by the series (4-RO-1H-pyrazolo [3,4-b] pyridin-5-yl)(phenyl)methanone (Figure 3) where RO was the alkoxy group with R being n-propyl (IC 50 =0.18 μM), n-butyl (0.11), 1-methylbutyl (0.24), 3-methylbutyl (0.18), n-pentyl (0.52), 2-hydroxyethyl (3.7), 2-dimethylaminoethyl (17), cyclohexyl (0.66), benzyl (0.28), phenyl (15) , and (4-RO-1H-pyrazolo[3,4-b]pyridin-5-yl)(phenyl-R)methanone where R was n-butyl and phenyl-R was 2,6-difluorophenyl, 2,6-difluoro-4-methyphenyl, 2,4,6-trimethylphenyl, 2-fluorophenyl and 2-methylphenyl.
13,14 ] Equations 6a and 6b are similar, with 6a being the better correlation. The differences between eq 6a and eq 6b reflects the stronger influence of the electrostatic bulk dehydration effect ΔG desolvation in eq 6b compared to the non-polar CDS (as in the ΔG desolv,CDS environment) in eq 6a on the inhibitory effect. As suggested in the introduction, the non-polar CDS parameter is a better representation of binding interaction with the kinase within the kinase binding pocket, where ε=6-10 compared to ε=78.3 for the bulk water environment, or ε=20-30 at the entry of the kinase binding pocket. Equations 6 and 6a show only small dependencies on dipole and molecular size, with water desolvation being the major influence on inhibitory binding, followed by a smaller dependency on lipophilicity. The phenoxy inhibitor is a strong outlier from both equations, and probably is attributable to a π stacking interaction or a steric clash with the kinase. The X-ray structure of the 4-butoxy substituent shows that the n-butyl group extends into the space occupied by the ribose of ATP and does not appear to form any specific contacts with the protein. The 2-dimethylaminoethyl groups is an outlier from eq 6a as well as the phenoxy group, which appears to indicate that some solvation around the -CH 2 NMe 2 group is significant and causes some interaction with the protein residues compared to the non-polar n-butyl group which shows no protein interaction. It is possible that the 2-dimethylaminoethyl inhibitor shows a larger deviation from the correlation in eq 6a, reflecting a stronger electrostatic contribution to hydration in eq 6b than the non-polar CDS hydration term in eq 6a (see eq 8 and 8a below).
IC 50 values (μM) for CDK2/cycE of the inhibitor series (4-RO-1H-pyrazolo[3,4-b]pyridin-5-yl)(phenyl)methanone where RO is the alkoxy group with R being n-propyl (0.18), n-butyl (0.11), 1-methylbutyl (0.24), 3-methylbutyl (0.18), n-pentyl (0.52), 2-hydroxyethyl (3.7), 2-dimethylaminoethyl (17), cyclohexyl (0.66), benzyl (0.28), phenyl (15) . R = phenyl omitted as outlier. Eq 7 only includes inhibitors where R is varied, and does not include any substituted phenyl-R compounds. Again the R = phenyl is a large outlier. The strong influence of water desolvation as found in eq 6 is indicative of the rearrangement of water molecules in the inner solvent shell of the inhibitors primarily around the N atoms of the pyrazole ring (the main hydrogen and polar binding site with the CDK). The variation in R groups has only a minor effect as manifested by the small changes to the ΔG lipophilicity term in equations 6 and 7. The small ΔG lipophilicity terms suggest little hydrophobic interaction between the R groups and the CDK protein. This is consistent with the x-ray structure which shows little interaction between any of the R groups and the CDK. The x-ray structure of the (4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,6 difluorophenyl)methanone shows that the 4-butoxy substituent extends into the space occupied by the ribose of ATP and does not appear to form any specific contacts with the protein while the pendant difluorophenyl ring lies buried within the protein, π stacking with Phe80. 13, 14 It is also clear that the pendant phenyl-R ring attached to the carbonyl group needs to be almost coplanar with the C=O group to allow in π stacking with the Phe80 of the protein. The minimal energy conformation of the 2,4,6-trimethylphenyl group attached to the carbonyl group is shown to be rotated almost orthogonally to the C=O plane, which prevents π stacking, and manifest itself in a very weak binding ability to the CDK. This is also consistent with the x-ray structure. 13, 14 It has been shown that substitution of the 1-H on the N1 of the pyrazole ring by an ethyl group in the inhibitor (3-methylbutyloxy-1-ethyl-pyrazolo[3,4-b]pyridin-5-yl)(phenyl)methanone leads to a very large lowering of activity, IC 50 > 25 compared to the 1-H pyrazole parent.
13,14 ] This change can obviously affect inhibitor hydration and lipophilicity simultaneously. Using eq 7 (which considers only the variation of activity of the 4-alkoxy inhibitors, and not inhibitor-CDK2 interaction via the pyrazolopyridine moiety) leads to a prediction that the IC 50 value is about 45. Since the hydrogen on N1 of the pyrazolopyridine ring serves as a H-bond donor to the carbonyl oxygen of Leu83 in the crystal structure of the complex of (4-n-butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(phenyl)methanone with CDK2, 13, 14 then the substitution of the 1-H on N1 by an 1-ethyl group prevents binding to the CDK2.
A more detailed thermochemical examination of the hydration of the CDK inhibitors has revealed that there is a linear relationship between ΔG desolv,CDS and ΔG desolvation and ΔH desolvation for 13 inhibitors. Quantitative structural activity relationships (QSAR) based on linear free energy changes in a series of active substrates can be observed if : (a) ΔH is linearly related to ΔS for the series, or (b) if ΔH is constant for the series, or (c) if ΔS is constant for the series. The non-polar hydration term ΔG desolv,CDS can be considered to comprise of the repulsive ΔG cavity and attractive ΔG vdw terms, and in this series, the ΔG cavity term should be proportional to changes in molecular volume, and ΔG vdw proportional to changes in interaction with the kinase. All structures were optimized in water in this study to allow the close examination of hydration effects on these inhibitors.
Hydration study of the inhibitor series (4-RO-1H-pyrazolo [3,4- Comparison of the highly significant eq 9 and eq10 show very similar activity dependencies for CDK2/cycE and CDK1/cycB, suggesting that these kinases have very similar binding behaviours and properties. The data set for the CDK4/cycD inhibitors is restricted to those where substitution of the pendant phenyl-R ring of the inhibitors has been made. Eq 11 and eq 12, are much less statistically significant than eqs 9 and 10, but show that the CDK4/cycD has a lower sensitivity to the 7 inhibitors, but the relative proportionate sensitivities to ΔG desolv,CDS and ΔG lipophilicity are similar, but the sensitivies to dipole and molecular size of the inhibitors are lower for the CDK4/cycD enzyme.
Modifying general eq 1 to incorporate redox properties
IC 50 values (μM) for CDK2/cycE of the inhibitor series (4-RO-1H-pyrazolo [3,4-b] pyridin-5-yl)(phenyl)methanone where RO is the alkoxy group with R being n-propyl (0.18), n-butyl (0.11), 1-methylbutyl (0.24), 3-methylbutyl (0.18), n-pentyl (0.52), 2-hydroxyethyl (3.7), 2-dimethylaminoethyl (17), cyclohexyl (0.66), benzyl (0.28), phenyl (15) , and (4-RO-1H-pyrazolo[3,4-b]pyridin-5-yl)(phenyl-R)methanone, where R was n-butyl and phenyl-R was R being n-butyl with phenyl-R being 2,6-difluorophenyl (0.064), 2,4,6-trifluorophenyl (0.036), 2,6-difluoro-4-methyphenyl (0.009), 2,6-difluoro-4-methoxyphenyl (0.022), 2,6-difluoro-4-chlorophenyl (0.027), 2,6-difluoro-4-bromophenyl (0.020), 2-fluorophenyl (0.036) and 2-methylphenyl (0.73). R = phenyl omitted as outlier. Eqs 13a and 13b show correlations using the electron affinity (EA) and ionization energy (IE) instead of the molecular volume term used in eqs 6a and 6b (where the coefficients are very small, and can be ignored) to probe whether redox reactions may be significant in the binding interactions of CDK2/cycE with the inhibitors. The correlations in eq 13a and 13b are of moderate significance, but do show a relationship between IC 50 and the redox properties, and the dominance of ΔG desolv,CDS . These observations suggest that redox reactions between the CDK2/cycE and inhibitors could involve non-polar water solvation effects. It can be seen that eqs 13a and 13b are almost identical to eqs 14a and 14b, suggesting that the redox properties of the CDK2/cycE are very similar to the CDK1/cycB complexes.
IC 50 values (μM) for CDK4/cycD of the inhibitor series (4-RO-1H-pyrazolo [3,4-b] pyridin-5-yl)(phenyl-R)methanone, where R was n-butyl and phenyl-R was R being n-butyl with phenyl-R being 2,6-difluorophenyl (0. The correlations in eq 15a and 15b appear to show that the redox behaviour of inhibitor inhibition of the CDK4/cycD complex is quite different from the CDK2/cycE and CDK1/cycB complexes. However these eqs 15 have a limited number of data points compared to eq 13 and 14, but the main difference seems to be a greater sensitivity to lipophilicity and dipole moment in eqs 15 compared to eqs 13 and 14. Eq 16 provides a direct comparison with eq 15a for the same data points, and it can be seen that the coefficients in eq 15a are far more sensitive to non-polar water desolvation energy, lipophilicity and dipole moment relative to the sensitivity to EA. It is known that redox potentials oscillate during the cell cycle, passing from a reductive to oxidative environment as the cycle progresses, and the redox potential increases in abnormal cell division such as apoptosis and necrosis, but decreases in normal cell division.
20 ( Figure 4 ) There is evidence that the CDK4/cycD has a strong reduction potential in the early G phase of the cell cycle, a weaker reduction potential later in the G phase or early S phase, but in the G2 to M phase of the cycle, CDK1/cycD has a strong oxidation potential. Eqs 15 and 13/14 are consistent with these known facets of cell cycle redox processes, and may be useful indicators of differences in cell cycle behaviour by allowing separation of desolvation, lipophilicity and dipole from electron transfer processes. All correlations using eq 1 and its variants in this study were conducted using identical conditions. 21 The Table lists the various drugs and their biophysical parameters that were used in all equations derived above. Previous studies of the cyclin-dependent kinase inhibitors and HIV-1 protease inhibitors have sought to confirm whether ligand-protein binding is dependent on desolvation effects. It has been found that a four parameter linear model incorporating desolvation energy, lipophilicity, dipole moment and molecular volume of the ligands is a good model to describe the binding between ligands and kinases or proteases. The resistance shown by MDR proteases to the anti-viral drugs is multi-faceted involving varying changes in desolvation, lipophilicity and dipole moment interaction compared to the non-resistant protease. Desolvation has been shown to be the dominant factor influencing the effect of inhibitors against the cyclindependent kinases, but lipophilicity and dipole moment are also significant factors. The model can differentiate between the inhibitory activity of CDK2/cycE, CDK1/cycB and CDK/cycD enzymes. been shown to give accurate electrostatic atomic charges, and was used to optimize the IEFPCM/SMD solvent model. With the 6-31G* basis set, the SMD model achieves mean unsigned errors of 0.6 -1.0 kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 4 kcal/mol on average for ions. 4 The 6-31G** basis set has been used to calculate absolute free energies of solvation and compare these data with experimental results for more than 500 neutral and charged compounds.
The calculated values were in good agreement with experimental results across a wide range of compounds. 22, 23 Adding diffuse functions to the 6-31G* basis set (ie 6-31 + G**)
had no significant effect on the solvation energies with a difference of less than 1% observed in solvents, which is within the literature error range for the IEFPCM/SMD solvent model. It is noted that high computational accuracy for each species in different environments is not the focus of this study, but comparative differences between various species is the aim of the study. 
